Do analysts rate PHVS or ZSQR?

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 60.10%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor PHVS or ZSQR?

In the previous week, Pharvaris had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Pharvaris and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.62 beat Pharvaris' score of 0.34 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend IMNM or ZSQR?

Immunome currently has a consensus target price of $33.17, indicating a potential upside of 80.45%. Given Immunome's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunome is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.85 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor IMNM or ZSQR?

In the previous week, Immunome had 6 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 9 mentions for Immunome and 3 mentions for Coeptis Therapeutics. Immunome's average media sentiment score of 0.68 beat Coeptis Therapeutics' score of 0.62 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HRMY or ZSQR?

Harmony Biosciences presently has a consensus target price of $40.89, suggesting a potential upside of 18.66%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Harmony Biosciences is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harmony Biosciences 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor HRMY or ZSQR?

In the previous week, Harmony Biosciences had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Harmony Biosciences and 3 mentions for Coeptis Therapeutics. Harmony Biosciences' average media sentiment score of 0.97 beat Coeptis Therapeutics' score of 0.62 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ZSQR or AUPH?

Aurinia Pharmaceuticals has a consensus target price of $17.25, indicating a potential upside of 9.04%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aurinia Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to ZSQR or AUPH?

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Coeptis Therapeutics' score of 0.62 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ZSQR or KOD?

Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 23.73%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Kodiak Sciences is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Does the media refer more to ZSQR or KOD?

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 3 articles in the media. Kodiak Sciences' average media sentiment score of 0.87 beat Coeptis Therapeutics' score of 0.62 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coeptis Therapeutics (ZSQR) Competitors

$10.93 +0.03 (+0.28%)

As of 06/12/2026 04:00 PM Eastern

Compare

ZSQR vs. PHVS, IMNM, HRMY, AUPH, and KOD

Should you buy Coeptis Therapeutics stock or one of its competitors? MarketBeat compares Coeptis Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coeptis Therapeutics include Pharvaris (PHVS), Immunome (IMNM), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Coeptis Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Coeptis Therapeutics (NASDAQ:ZSQR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Coeptis Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Coeptis Therapeutics	$1.36M	413.33	-$11.92M	-$2.52	N/A

Pharvaris has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market.

Pharvaris has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Pharvaris' return on equity of -67.56% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 60.10%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pharvaris had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for Pharvaris and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.62 beat Pharvaris' score of 0.34 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Coeptis Therapeutics beats Pharvaris on 8 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and Coeptis Therapeutics (NASDAQ:ZSQR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Immunome currently has a consensus target price of $33.17, indicating a potential upside of 80.45%. Given Immunome's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunome is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coeptis Therapeutics has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	299.93	-$212.39M	-$2.38	N/A
Coeptis Therapeutics	$1.36M	413.33	-$11.92M	-$2.52	N/A

In the previous week, Immunome had 6 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 9 mentions for Immunome and 3 mentions for Coeptis Therapeutics. Immunome's average media sentiment score of 0.68 beat Coeptis Therapeutics' score of 0.62 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.6% of Immunome shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunome has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market.

Immunome has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Immunome's return on equity of -51.15% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Immunome beats Coeptis Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Harmony Biosciences has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.30	$158.69M	$2.48	13.90
Coeptis Therapeutics	$1.36M	413.33	-$11.92M	-$2.52	N/A

Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

Harmony Biosciences presently has a consensus target price of $40.89, suggesting a potential upside of 18.66%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Harmony Biosciences is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Harmony Biosciences has a net margin of 16.20% compared to Coeptis Therapeutics' net margin of -810.04%. Harmony Biosciences' return on equity of 17.19% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

In the previous week, Harmony Biosciences had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Harmony Biosciences and 3 mentions for Coeptis Therapeutics. Harmony Biosciences' average media sentiment score of 0.97 beat Coeptis Therapeutics' score of 0.62 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harmony Biosciences beats Coeptis Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Aurinia Pharmaceuticals?

Coeptis Therapeutics (NASDAQ:ZSQR) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Aurinia Pharmaceuticals has a consensus target price of $17.25, indicating a potential upside of 9.04%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Coeptis Therapeutics has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Coeptis Therapeutics' net margin of -810.04%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Coeptis Therapeutics' score of 0.62 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	413.33	-$11.92M	-$2.52	N/A
Aurinia Pharmaceuticals	$283.05M	7.19	$287.20M	$2.17	7.29

Summary

Aurinia Pharmaceuticals beats Coeptis Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Kodiak Sciences?

Coeptis Therapeutics (NASDAQ:ZSQR) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Kodiak Sciences has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Coeptis Therapeutics' return on equity of -92.29% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Kodiak Sciences	N/A	-253.85%	-81.48%

Coeptis Therapeutics has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 23.73%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Kodiak Sciences is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Coeptis Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	413.33	-$11.92M	-$2.52	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 3 articles in the media. Kodiak Sciences' average media sentiment score of 0.87 beat Coeptis Therapeutics' score of 0.62 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kodiak Sciences beats Coeptis Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$561.89M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-4.34	19.82	24.21	24.42
Price / Sales	413.33	305.72	512.05	109.98
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	4.16	8.32	10.66	6.83
Net Income	-$11.92M	$23.94M	$3.57B	$337.67M
7 Day Performance	8.00%	3.53%	0.84%	2.68%
1 Month Performance	11.08%	-2.55%	-0.34%	1.56%
1 Year Performance	30.74%	44.82%	25.40%	30.59%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZSQR Coeptis Therapeutics	0.2919 of 5 stars	$10.93 +0.3%	N/A	+30.7%	$561.89M	$1.36M	N/A	2	News Coverage Analyst Downgrade
PHVS Pharvaris	3.3169 of 5 stars	$31.51 -0.3%	$49.18 +56.1%	+84.0%	$2.06B	N/A	N/A	30	News Coverage
IMNM Immunome	3.6684 of 5 stars	$18.16 -1.3%	$33.17 +82.6%	+99.8%	$2.06B	$6.94M	N/A	40	News Coverage Analyst Forecast Insider Trade
HRMY Harmony Biosciences	4.484 of 5 stars	$35.48 +4.0%	$40.89 +15.2%	+4.5%	$2.05B	$868.45M	14.31	200	News Coverage High Trading Volume
AUPH Aurinia Pharmaceuticals	2.7442 of 5 stars	$15.66 -0.8%	$17.25 +10.2%	+93.4%	$2.01B	$283.05M	7.22	300	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. PHVS, IMNM, HRMY, AUPH, and KOD

How does Coeptis Therapeutics compare to Pharvaris?

Summary

How does Coeptis Therapeutics compare to Immunome?

Summary

How does Coeptis Therapeutics compare to Harmony Biosciences?

Summary

How does Coeptis Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Coeptis Therapeutics compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. PHVS, IMNM, HRMY, AUPH, and KOD

How does Coeptis Therapeutics compare to Pharvaris?

Do insiders and institutionals have more ownership in PHVS or ZSQR?

Which has higher earnings and valuation, PHVS or ZSQR?

Which has more volatility & risk, PHVS or ZSQR?

Is PHVS or ZSQR more profitable?

Do analysts rate PHVS or ZSQR?

Does the media favor PHVS or ZSQR?

Summary

How does Coeptis Therapeutics compare to Immunome?

Do analysts recommend IMNM or ZSQR?

Which has preferable valuation & earnings, IMNM or ZSQR?

Does the media favor IMNM or ZSQR?

Do insiders & institutionals have more ownership in IMNM or ZSQR?

Which has more risk and volatility, IMNM or ZSQR?

Is IMNM or ZSQR more profitable?

Summary

How does Coeptis Therapeutics compare to Harmony Biosciences?

Do insiders and institutionals believe in HRMY or ZSQR?

Which has preferable earnings & valuation, HRMY or ZSQR?

Which has more volatility & risk, HRMY or ZSQR?

Do analysts recommend HRMY or ZSQR?

Is HRMY or ZSQR more profitable?

Does the media favor HRMY or ZSQR?

Summary

How does Coeptis Therapeutics compare to Aurinia Pharmaceuticals?

Do analysts prefer ZSQR or AUPH?

Do institutionals and insiders believe in ZSQR or AUPH?

Which has more volatility & risk, ZSQR or AUPH?

Is ZSQR or AUPH more profitable?

Does the media refer more to ZSQR or AUPH?

Which has higher earnings & valuation, ZSQR or AUPH?

Summary

How does Coeptis Therapeutics compare to Kodiak Sciences?

Is ZSQR or KOD more profitable?

Which has more volatility & risk, ZSQR or KOD?

Do insiders & institutionals hold more shares of ZSQR or KOD?

Do analysts recommend ZSQR or KOD?

Which has preferable earnings and valuation, ZSQR or KOD?

Does the media refer more to ZSQR or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools